Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Kfar Saba, Israel Clinical Trials

A listing of Kfar Saba, Israel clinical trials actively recruiting patients volunteers.

RESULTS

Found (27) clinical trials

Improving the Function and Welfare of Late-stage Solid Cancer Subjects by ACC Administered Orally and Concomitantly With Inhalation

To improve the function and welfare of late stage solid cancer subjects by: enabling subjects to benefit from a potentially promising drug under development assessing initial evidence of improvement in Pain VAS score assessing initial improvement in Performance Status (PS) assessing initial improvement in oxygen saturation whenever it is feasible

Phase

0.0 miles

Learn More »

Study of MK-7684 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)

This is a safety, efficacy, and pharmacokinetics study of MK-7684 as monotherapy and in combination with pembrolizumab (MK-3475) in adults with metastatic solid tumors for which there is no available therapy that is expected to convey clinical benefit. Part A of this study is a dose escalation phase. Part B ...

Phase

2.39 miles

Learn More »

Study of MK-4280 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-4280-001)

This is a safety and pharmacokinetics study of MK-4280 as monotherapy and in combination with pembrolizumab (MK-3475) in adults with metastatic solid tumors for which there is no available therapy which may convey clinical benefit. Part A of this study is a dose escalation design in which participants receive MK-4280 ...

Phase

2.39 miles

Learn More »

A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors

This is a Phase 1b study that incorporates dose expansion cohorts to further evaluate promising clinical or biological activity.

Phase

6.61 miles

Learn More »

A Study of Safety Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

This study has 2 parts: Dose Escalation (part 1) and Dose Expansion (part 2) which are conducted in 3 phases: Screening Phase (up to 28 days prior to first dose of study drug and includes procedures like electrocardiogram [ECG], serum pregnancy test), Treatment phase (continues until the completion of the ...

Phase

6.61 miles

Learn More »

Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL

Acute lymphoblastic leukemia (ALL) is an aggressive type of leukemia characterized by an overproduction of lymphoblasts or lymphocytes in the bone marrow and the peripheral blood; it is frequently accompanied by suppression of normal hematopoiesis. It can spread to the lymph nodes, spleen, liver, the central nervous system (CNS), and ...

Phase

6.61 miles

Learn More »

Phase I Pharmacokinetics and Safety Study of Naloxegol in Paediatric OIC Patients

To characterize the pharmacokinetics (PK) of naloxegol after single oral dose and through population PK in paediatric patients with opioid induced constipation (OIC).

Phase

6.61 miles

Learn More »

Ilaris (Canakinumab) in Patient With Periodic Fever Aphthous Stomatitis Pharyngitis and Cervical Adenitis (PFAPA)

Study Objectives: Primary objective: Patients will experience at least 50% reduction in PFAPA flares for the next 2 consecutive months after receiving single dose of canakinumab (4 mg/kg). Secondary objectives: Time to flare Parent/patient quality of life assessment Study rationale: Periodic Fever, Aphthous stomatitis, Pharyngitis and cervical Adenitis (PFAPA) is ...

Phase

6.61 miles

Learn More »

Study of MK-1454 Alone or in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors or Lymphomas (MK-1454-001)

Participants will receive either MK-1454 monotherapy or MK-1454 in combination with pembrolizumab for up to 35 cycles (approximately 2 years). Participants will undergo at least a 24-hour observation period following the first dose administration of MK-1454 on Cycle 1, Day 1.

Phase

9.0 miles

Learn More »

Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001)

Participants will receive either MK-2118 monotherapy or MK-2118 in combination with pembrolizumab for up to 35 cycles (approximately 2 years). All participants will undergo an at least 24-hour observation period following the first dose administration of MK-2118 on Cycle 1, Day 1.

Phase

9.0 miles

Learn More »